- 1.
- McDonagh MS, Peterson K, Thakurta S, Low A. Drug class review: Pharmacologic treatments for attention deficit hyperactivity disorder: final update 4 report [Internet]. Portland (OR): Oregon Health & Science University; Dec, 2011. [cited 2016 Feb 2]. (Drug Class Reviews). Available from: http://www
.ncbi.nlm.nih .gov/books/NBK84419 /pdf/Bookshelf_NBK84419.pdf. [PubMed: 22420008] - 2.
- López FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. Atten Defic Hyperact Disord [Internet]. Sep, 2013. [cited 2016 Feb 2]. pp. 249–265. Available from: http://www
.ncbi.nlm.nih .gov/pmc/articles/PMC3751218. [PMC free article: PMC3751218] [PubMed: 23564273] - 3.
- Canadian ADHD practice guidelines (CAP-guidelines) [Internet]. 3rd ed. Toronto: Canadian ADHD Resource Alliance; 2011. [cited 2016 Feb 17]. Available from: http://www
.caddra.ca /pdfs/caddraGuidelines2011.pdf. - 4.
- Anderton P, Brown S. Justice and ADHD [Internet]. Chorley, United Kingdom: ADHD and crime generally; 2016. [cited 2016 Feb 18]. Available from: http://www
.adhdandjustice .co.uk/badge/adhd-and-crime-generally.aspx. - 5.
- Adler LA, Lynch LR, Shaw DM, Wallace SP, Ciranni MA, Briggie AM, et al. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. Postgrad Med. 2011 Sep;123(5):71–79. [PubMed: 21904088]
- 6.
- Gibson AP, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006 Jun;40(6):1134–1142. [PubMed: 16735655]
- 7.
- Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med [Internet]. Nov 22, 2012. [cited 2016 Feb 18]. pp. 2006–2014. Available from: http://www
.ncbi.nlm.nih .gov/pmc/articles/PMC3664186. [PMC free article: PMC3664186] [PubMed: 23171097] - 8.
- Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the hyperkinetic disorders: A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006 Dec;15(8):476–495. [PubMed: 16680409]
Publication Details
Copyright
Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a website, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.
Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher
Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
NLM Citation
Combination Therapy for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Feb 23. REFERENCES.